Aims Dual pathway inhibition (DPI) by adding a vascular dose of rivaroxaban to a single
antiplatelet agent has emerged as a promising antithrombotic strategy. However, in most …

Aim Inhibition of thrombin-mediated signaling processes using a vascular dose of
rivaroxaban in adjunct to antiplatelet therapy, known as dual-pathway inhibition (DPI) …

Background To date, there are no data on switching to dual pathway inhibition (DPI) patients
who have completed a guideline-recommended dual antiplatelet therapy (DAPT) regimen …

Aims To determine the characteristics of patients with coronary artery disease (CAD),
peripheral artery disease (PAD), or both, initiating dual pathway inhibition (DPI) using …

Introduction The persistence of elevated rates of ischemic recurrences despite the use of
antiplatelet therapy among patients with atherosclerotic disease together with the …

Risk-based antithrombotic strategies after percutaneous coronary intervention (PCI). Dual
antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is indicated for …

Dual antiplatelet therapy (DAPT)—a combination of a P2Y 12 receptor inhibitor and aspirin—
has revolutionized antithrombotic treatment. Potent P2Y 12 inhibitors such as prasugrel and …

Background Among patients treated with a novel oral anticoagulant (NOAC) undergoing
percutaneous coronary intervention (PCI), combination therapy with clopidogrel (ie, known …

Background Dual antiplatelet therapy (DAPT), aspirin plus a P2Y12 inhibitor, is the standard
antithrombotic treatment following acute coronary syndromes. The factor Xa inhibitor …

The novel clopidogrel conjugate, DT‐678, is an effective inhibitor of platelets and thrombosis
in preclinical studies. However, a comparison of the bleeding risk with DT‐678 and currently …